ExonHit Announces the Inclusion of Proprietary Lead Compounds into Allergan Collaboration
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
ExonHit Therapeutics has announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan
ExonHit Therapeutics has announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
"We are very fortunate to have a strong and productive partnership with Allergan, which allows both companies to take advantage of opportunities to shorten development timelines and rapidly move to create new shared products and value," stated Loic Maurel M.D., President of ExonHit Therapeutics' Management Board.
ExonHit will continue to lead the medicinal chemistry effort related to this target. The compounds are active against a new enzyme target potentially useful for therapeutic development in ophthalmology and neurodegenerative indications.
Milestone and royalty terms of the existing collaboration agreement will apply to these compounds and the products derived from them.
ExonHit Therapeutics has announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
"We are very fortunate to have a strong and productive partnership with Allergan, which allows both companies to take advantage of opportunities to shorten development timelines and rapidly move to create new shared products and value," stated Loic Maurel M.D., President of ExonHit Therapeutics' Management Board.
ExonHit will continue to lead the medicinal chemistry effort related to this target. The compounds are active against a new enzyme target potentially useful for therapeutic development in ophthalmology and neurodegenerative indications.
Milestone and royalty terms of the existing collaboration agreement will apply to these compounds and the products derived from them.
